معرفی
Professor Tim Aitman serves as Chair of Molecular Pathology and Genetics and Director of the Centre for Genomic and Experimental Medicine within the University of Edinburgh’s Institute of Genetics and Cancer, holding an Honorary Consultant Physician position with NHS Lothian. He leads the Scottish Genomes Partnership and founded the One Health Genomics Edinburgh network with over 600 researchers. His affiliations extend to the CRUK Edinburgh Centre and BioCaptiva, a spinout company developing cell-free DNA capture technology.
His research integrates classical genetics with cutting-edge genomic technologies to investigate rare and common human disorders. Key focus areas include:
- Genetic basis of insulin resistance syndromes and autoimmune diseases like systemic lupus
- Next-generation sequencing for rare disease diagnosis (familial hypercholesterolemia, Ehlers-Danlos, nephrotic syndrome)
- Liquid biopsy development for cancer stratification using cell-free DNA analysis
- Evolutionary genomics through rat genome sequencing projects
Professor Aitman’s publication portfolio shows strong emphasis on translational genomics, with recent articles focusing on liquid biopsy applications in prostate cancer radiotherapy, acute aortic syndromes, and oropharyngeal cancer. His research consistently bridges basic genomic discovery with clinical implementation, particularly in cancer diagnostics and rare disease genomics.
His scientific recognition includes:
- Fellowship in the Royal Colleges of Physicians of London and Edinburgh
- Fellowship in the Academy of Medical Sciences
- Senior Fellowship at the PHG Foundation
- Specialist Adviser for the House of Lords Science and Technology Committee
As principal investigator, he has secured over £30 million in research funding from major bodies including MRC, ERC, CRUK, and AstraZeneca. His leadership extends to the BioCaptiva spinout (£3M+ investment) and the University of Edinburgh’s COVID-19 testing program (TestEd). Current projects focus on cell-free DNA biomarkers for radiotherapy adaptation and acute disease monitoring.
He directs the Centre for Genomic and Experimental Medicine at Edinburgh’s Western General Hospital campus, fostering collaborations across the Institute of Genetics and Cancer. His One Health Genomics network integrates veterinary and human genomic research, while partnerships with CRUK Edinburgh Centre and NHS Lothian drive clinical translation of genomic technologies.
